Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

British Journal of Cancer

Volumn 83, Issue 1, 2000, Pages 91-94

  Saso, R ^a   Kulkarni, S ^a   Mitchell, P ^b   Treleaven, J ^a   Swansbury, G J ^a   Mehta, J ^c   Powles, R ^a   Ashley, S ^d   Kuan, A ^a   Powles, T ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b AUSTIN HEALTH   (Australia)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Thames Cancer Registry   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Breast cancer; Mitoxantrone; Myelodysplastic syndrome

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034079462     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1196     Document Type: Article

References (25)

1. Aul C, Gattermann N and Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82: 358-367
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gahon DA, Gralnick HR and Sultan C (1982) FAB Cooperative Group. Proposals for the classification of myelodysplastic syndromes. Br J Haematol 51: 189-199
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick HR and Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 620-625
4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M and Terenziani M (1993) Risk of acute leukemia and other malignances following CMF-based adjuvant chemotherapy for breast cancer. Proceedings of the American Society of Clinical Oncologists 12: 61 (abstr 45)
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M and Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901-906
6. Breslow NE and Day NE (1987) The design and analysis of cohort studies. In Statistical methods in Cancer Research, Vol 2. pp 1-406. IARC Scientific Publications: Lyon
7. Brincker H, Rose C, Maase H and Dombernowsky P (1983) A randomized study of CAF-TAM (Tamoxifen) versus CMF + TAM in metastatic breast cancer. Proceedings of the American Society of Clinical Oncologists 3-113
8. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M and Hortobagyi GN (1996) Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center Experience. J Clin Oncol 14: 2722-2730
9. Ellis M, Ravid M and Lishner M (1993) A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 11. 9-13
10. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L and Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89 1673-1682
11. Henderson IC, Garber JE, Breitmeyer JB and Hayesris JR (1990) Comprehensive management of disseminated breast cancer. Cancer 66: 1439-1448
12. Johansson B, Mertens F and Mitelman F (1996) Secondary neoplasia-associated chromosomal abnormalities-Balanced rearrangements vs genomic imbalances? Genes Chromosomes Cancer 16: 155-163
13. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. American Statistical Association Journal 53. 457-481
14. Mitchell PL, Treleaven JG, Swansbury GJ, Powles RL, Ashley S and Powles T (1996) Secondary acute myeloid leukaemia (AML) and myelodysplasia (MDS) following mitoxantrone given as adjuvant therapy for breast cancer. Proceedings of the American Society of Clinical Oncologists 12: 127
15. Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J and Treleaven J (1993) A toxic interaction betwen mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 29A: 1854-1857
16. Pedersen-Bjergaard J and Rowley J (1994) The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83: 2780-2786
17. Philpott NJ, Bevan DH and Gordon-Smith EC (1993) Secondary leukaemia after MMM combined modality therapy for breast carcinoma. Lancet 341: 1289
18. Powles TJ, Jones AL and Judson IR, et al. (1991) A randomised trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 64: 406-410
19. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien M, Tidy VA, Casey S, Nash A, Sacks N, Cosgrove D, MacVicar D, Fernando I and Ford HT (1995) Randomized trial of chemoendocrine therapy started before and after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552
20. Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foscett M, Fuller S and Short D (1996) Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 14 2769-2773
21. Skuse GR and Ludlow JW (1995) Tumour suppressor genes in disease and therapy. Lancet 345: 902-906
22. Smith MA, McCaffrey RP and Karp JE (1996) The secondary leukemias: Challenges and research directions. J Natl Cancer Inst 88: 407-418
23. Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM and Wiernik PH (1995) Leukemogenic potential of adjuvant chemotherapy for early stage breast cancer: The Eastern Cooperative oncology group experience. J Clin Oncol 13: 1557-1563
24. Thirman MJ and Larson RA (1996) Therapy related myeloid leukemia. Hematol Oncol Clin North Am 10: 293-320
25. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ and Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87: 743-745